Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.

@article{Aric2008LongtermRO,
  title={Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.},
  author={M. Rita Aric{\`o} and Maria Grazia Valsecchi and Carmelo Rizzari and Elena Barisone and Andrea Biondi and Fiorina Casale and Franco Locatelli and Luca Lo Nigro and Matteo Luciani and Chiara Messina and Concetta Micalizzi and Rosanna Parasole and Andrea Pession and Nicola Santoro and Anna Maria Testi and Daniela Malinverni Silvestri and Giuseppe Basso and Giuseppe Masera and Valentino Conter},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 2},
  pages={283-9}
}
PURPOSE Between May 1995 and August 2000 the Associazione Italiana di Ematologia Oncologia Pediatrica conducted the ALL-95 study for risk-directed, Berlin-Frankfurt-Muenster (BFM) -oriented therapy of childhood acute lymphoblastic leukemia, aimed at exploring treatment reduction in standard-risk patients (SR) and intensification during continuation therapy in intermediate-risk patients (IR) as randomized questions and treatment intensification in high-risk patients (HR). The prognostic value of… CONTINUE READING